Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 262 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure
Interventions
AZD4831 Oral Myeloperoxidase Inhibitor, Placebo oral capsule
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Exercise Cardiovascular Magnetic Resonance
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Recruiting Not applicable Interventional

Inspiratory Muscle Training in HFpEF

NCT06510231
Conditions
Heart Failure
Interventions
Inspiratory Muscle Training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 2 Interventional Results available

Cilostazol for HFpEF

NCT05126836
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Cilostazol 100Mg Tab, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Conditions
Congestive Heart Failure
Interventions
blood volume measurement, venous plethysmography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 110 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention, Standard of Care (SOC)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases
Interventions
HBCR
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Rate Adaptive Pacing
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Rochester, Minnesota • Kansas City, Missouri • Cincinnati, Ohio + 2 more
Conditions
Heart Failure
Interventions
Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Beverly Hills, California • Lake Forest, California • Santa Maria, California + 17 more
Completed Early Phase 1 Interventional Results available

Pressure Assessment to Improve Outcomes After TAVR: a Registry

NCT03923530
Conditions
Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions
Eplerenone
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
55 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
11,265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
Interventions
Semaglutide, Placebo, Counselling on healthy lifestyle intervention
Drug · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
IW-1973, Placebo Oral Tablet
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
45 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more
Conditions
Chronic Heart Failure (CHF)
Interventions
LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
Conditions
Heart Failure
Interventions
BMS-986435, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 85 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Lakewood, Colorado • Jacksonville, Florida + 18 more
Conditions
Heart Failure With Preserved Ejection Fraction, Hypertension
Interventions
Amlodipine Besylate, Metoprolol Succinate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Gamification plus social incentive, Gamification plus competition
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania